ArticleCurrent oncology (Toronto, Ont.)2023

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer.

Alberto Alvarado-Miranda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.